Merck: FDA grants priority review to Ebola vaccine
(CercleFinance.com) - Merck said its experimental Ebola vaccine has been granted a priority review status by the US Food and Drug Administration, which will accelerate the regulatory process by months.
The US drugmaker said the FDA has accepted its biologics license application (BLA) with a target action date that has been set for March 2020.
In July 2016, the FDA granted the "breakthrough therapy" designation to the vaccine.
The Merck stock was up 0.4% at 82.4 dollars in early morning trading on Wall Street on Tuesday.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US drugmaker said the FDA has accepted its biologics license application (BLA) with a target action date that has been set for March 2020.
In July 2016, the FDA granted the "breakthrough therapy" designation to the vaccine.
The Merck stock was up 0.4% at 82.4 dollars in early morning trading on Wall Street on Tuesday.
Copyright (c) 2019 CercleFinance.com. All rights reserved.